Aspects concerning busulfan pharmacokinetics and bioavailability

Leukemia and Lymphoma

Volumn 22, Issue 5-6, 1996, Pages 395-407

  Hassan, Moustapha ^a   Ehrsson, Hans ^a   Ljungman, Per ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bioavailability; Busulfan; Pharmacokinetics

Indexed keywords

BUSULFAN; CLONAZEPAM; CYCLOPHOSPHAMIDE; DIAZEPAM; PHENYTOIN;

ADDISON DISEASE; ALLOGENIC BONE MARROW TRANSPLANTATION; ALOPECIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD BRAIN BARRIER; BONE MARROW DEPRESSION; CATARACT; CHRONIC GRANULOMATOUS DISEASE; CIRCADIAN RHYTHM; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG FATALITY; DRUG MONITORING; ENDOCARDIAL DISEASE; ENDOCRINE DISEASE; GRAFT FAILURE; GROWTH DISORDER; HUMAN; HYPERPIGMENTATION; LEUKEMIA; LIVER FUNCTION; LUNG FIBROSIS; MORTALITY; MYASTHENIA GRAVIS; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; POLYCYTHEMIA VERA; PRIORITY JOURNAL; REVIEW; SEIZURE; THROMBOCYTHEMIA; VEIN OCCLUSION;

EID: 0029848690     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199609054777     Document Type: Review

References (130)

1. Haddow, A. and Timmis, G. M. (1953) MyIeran in chronic myeloid leukaemia. Lancet, I, 207.
2. Galton, D. A. G. (1953) Myleran in chronic leukemia: result of treatment. Lancet, I, 208.
3. Galton, D. A. G. (1969) Chemotherapy of chronic myelocytic leukemia. Semin. Hematol., 6, 323.
4. Singer, C. R. J., McDonald, G. A. and Douglas, A. S. (1984) Twenty-five year survival of chronic granulocytic leukaemia with spontaneous karyotype conversion. Br. J. Haematol., 57, 309.
5. Desai, R. G. (1959) Treatment of chronic granolycytjc and lymphatic leukemia and allied disorders with Myleran and Leukeran in Indian Subjects. Acta. Hematol. Jpn., 22, 160.
6. Sokal, J. E. (1973) Current concepts in the treatment of chronic myelocytic leukemia. Annu. Rev. Med., 24, 281.
7. Haut, A., Abbott, W. S., Wintrobe, M. M. and Cartwright, G. E. (1961) Busulfan in the treatment of chronic myelocytic leukemia. The effect of long-term intermittent therapy. Blood, 17, 1.
8. 1-positive cells and lymphocytes from patients with chronic myeloid leukaemia. Mutat. Res., 81, 81.
9. Hunstein, W. (1974) Therapeutic considerations in chronic myeloid leukemia. Med. Clin., 69, 412.
10. 32P and Myleran: Development of chronic granulocytic leukemia with chromosomal abnormalities in one patient. Clin. Genet., 7, 227.
11. Ernst, P., Nielsen, J. B. and Killman, S.-A. (1971) Treatment of polycythaemia vera. Nord. Med., 86, 1533.
12. Brodsky, I. (1982) Busulfan: Effect on platelet RNA dependent DNA polymease-implications in the treatment of polycythemia vera, thrombosis and atherosclerosis. Biomedicine, 36, 125.
13. Brodsky, I., Fuscaldo, A. A., Erlick, B. J. and Fuscaldo, K. E. (1977) Effect of busulfan on oncornavirus-like activity in platelets and chromosomes in polycythemia vera and essential thrombocythemia. J. Natl. Cancer Inst., 59, 61.
14. Van de Pette, J. E. W., Prochazka, A. V., Pearson, T. C., Singh, A. K., Dickson, E. R. and Wetherley-Mein, G. (1986) Primary thrombocythaemia treated with busulfan. Br. J. Haematol, 62, 229.
15. Rowland, L. P. (1971) Immunosuppressive drugs in treatment of myastheniagravis. Ann. N.Y. Acad. Sci., 183, 351.
16. Thompson, E. N. (1974) Chronic granulomatous disease. Clin. Pathol., 27, 933.
17. Weatherall, D. J., Galton, D. A. G. and Kay, H. E. M. (1969) Busulfan and bone marrow depression. Br. J. Med., 1, 638.
18. Ganda, O. P. and Mangalik, A. (1973) Delayed toxic effect of busulfan on the marrow. J. Assoc. Physens. India, 21, 511.
19. Elson, L. A. (1958) The effect of Myleran (1:4-dimethanesulphonyloxybutane) and homologous compounds on the blood. Biochem. Pharmacol., 1, 39.
20. Leonard, A. and Léonard, E. D. (1978) Cytogenetic effects of Myleran in vivo on bone-marrow cells from male mice. Mutat. Res., 56, 329.
21. Kirschner, R. H. and Esterly, J. R. (1971) Pulmonary lesions associated with busulfan therapy of chronic myelogenous leukemia. Cancer, 27, 1074.
22. Rosenow, III E. C. (1972) The spectrum of drug-induced pulmonary disease. Ann. Intern. Med., 77, 977.
23. Aymard, J.-P., Gyger, M., Lavallee, R., Legresley, L.-P. and Desy, M. (1984) A case of pulmonary alveolar proteinosis complicating chronic myelogenous leukemia: A peculiar pathologic aspect of busulfan lung? Cancer, 53, 954.
24. Burns, W. A., McFarland, W. and Matthews, M. J. (1970) Busulfan-induced pulmonary disease: Report of a case and review of the literature. Am. Rev. Respir. Dis., 101, 408.
25. Koch, H. and Lesch, R. (1976) Busulfan lung, pulmonary fibrosis caused by Myleran. Med. Welt., 27, 308.
26. Willson, J. K. V. (1978) Pulmonary toxicity of antineoplastic drugs. Cancer Treat. Rep., 62, 2003.
27. Ravindranathan, M. P., Paul, V. J. and Kuriakose, E. T. (1972) Cataract after busulfan treatment. Br. Med. J., 1, 218.
28. Dahlgren, S., Holm, G., Svanborg, N. and Watz, R. (1972) Clinical and morphological side-effects of busulfan (Myleran) treatment. Acta. Med. Scand., 192, 129.
29. Harrold, B. P. (1966) Syndrome resembling Addison's disease following prolonged treatment with busulfan. Br. Med. J., 1, 463.
30. Levantine, A. and Almeyda, J. (1974) Cutaneous reactions to cytostatic agents. Br. J. Dermatol., 90, 239.
31. Weinberger, A., Pinkhas, J., Sandbank, U., Shaklai, M. and de Vries, A. (1975) Endocardial fibrosis following busulfan treatment. JAMA, 231, 495.
32. Bishop, J. B. and Wassom, J. S. (1986) Toxicological review of busulfan (Myleran). Mutat. Res., 168, 15.
33. Santos, G. W., Tutschka, P. J., Brookmeyer, R., Saral, R., Berschorner, W. E., Bias, W. B., Braine, H. G., Burns, W. H., Elfenbein, G. J., Kaizer, H., Mellits, D., Sensenbrenner, L. L., Stuart, R. K. and Yeager, A. M. (1983) Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N. Engl. J. Med., 309, 1347.
34. Lu, C., Braine, H. G., Kaizer, H., Saral, R., Tutschka, P. J. and Santos, G. W. (1984) Preliminary results of high dose busulfan and cyclophosphamide with syngeneic or autologous bone marrow rescue. Cancer Treat. Rep., 68, 711.
35. Geller, R. B., Saral, R., Piantadosi, S., Zahurak, M., Vogelsang, G. B., Wingard, J. R., Ambinder, R. F., Beschorner, W. B., Braine, H. G., Burns, W. H., Hess, A. D., Jones, R. J., May, W. S., Rowley, S. D., Wagner, J. E., Yeager, A. M. and Santos, G. W. (1989) Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. Blood, 73, 2209.
36. Nevill, T. J., Shepherd, J. D., Reece, D. E., Barnett, M. J., Nantel, S. H., Klingemann, H.-G. and Phillips, G. L. (1992) Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant., 10, 445.
37. Ratanatharathorn, V., Karanes, C., Uberti, J., Lum, L. G., de Planque, M. M., Schultz, K. R., Cronin, S., Dan, M. E., Mohamed, A., Hussein, M. and Sensenbrenner, L. L. (1993) Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood, 81, 2194.
38. Blazar, B. R., Ramsay, N. K. C., Kersey, J. H., Krivit, W., Arthur, D. C. and Filipovich, A. H. (1985) Pretransplant conditioning with busulfan (Myleran) and cyclophosphamide for nonmalignant diseases. Transplantation, 39, 597.
39. Krivit, W., Whitley, C. B., Chang, P. N., Belani, K. G., Snover, D., Summers, C. G. and Blazar, B. (1990) Lysosomal storage diseases treated by bone marrow transplantation: Review of 21 patients, in Johnson, L., Pochedly, C. (eds), Bone Marrow Transplantation in children. New York, NY, Liss, p261.
40. Shaw, P. J., Hugh-Jones, K., Barrett, A. J., Desai, S. J. S. and Hobbs, J. R. (1985) Experience with busulfan and cyclophosphamide as pre-graft conditioning regime in inborn errors of me-tabolism. Exp. Hematol. suppl. 17, 13, 92.
41. Lucarelli, G., Galimberti, M., Delfini, C., Agostinelli, F., Giorgi, C., Giardini, C., Polchi, P., Izzi, T., Manna, M., Baronciani, D., Angelucci, E., Politi, P. and Manenti, F. (1985) Marrow transplantation for thalassaemia following busulfan and cyclophosphamide. Lancet, 1, 1355.
42. Hobbs, J. R., Hugh-Jones, K., Shaw, P. J., Downie, C. J. C. and Williamson, S. (1986) Engraftment rates related to busulfan and cyclophosphamide dosages for displacement bone marrow transplants in fifty children. Bone Marrow Transplant., 1, 201.
43. Fischer, A., Friedrich, W., Morgan, G., Wagemaker, G., Griscelli, C., Kuranek, B., Levinsky, R., Vossen, D. and Landais, P. (1986) Bone marrow transplantation for immune deficiencies and osteopetrosis: A European survey 1968-1985. Lancet, 2, 1058.
44. Santos, G. W. (1989) Busulfan and cyclophosphamide for marrow transplantation. Bone Marrow Transplant., 4, 236.
45. Parkman, R., Rappeport, J. M., Hellman, S., Lipton, J., Smith, B., Geha, R. and Nathan, D. G. (1984) Busulfan and total body irradiation as antihematopoietic stem cell agents in preparation of patients with congenital bone marrow disorders for allogeneic bone marrow transplantation. Blood, 64, 852.
46. Brodsky, R., Topolsky, D., Crilley, P., Bulova, S. and Brodsky, I. (1990) Frequency of veno-occlusive disease of the liver in bone marrow transplantation with a modified busulfan/cyclophos-phamide preparative regimen. Amer. J. Clin. Oncol., 13, 221.
47. MacDonald, G. B., Hinds, M. S., Fisher, L. D., Schoch, H. G., Wolford, J. L., Banaji, M., Hardin, B. J., Shulman, H. M. and Clift, R. A. (1993) Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann. Intern. Med., 118, 255.
48. Shulman, H. M. and Hinterberger, W. (1992) Hepatic veno-occlusive disease-liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplant., 10, 197.
49. Perry, M. C. (1992) Chemotherapeutic agents and hepatotoxicity. Seminars in Oncol., 19, 551.
50. Grochow, L. B., Jones, R. J., Brundrett, R. B., Braine, H. G., Chen, T.-L., Saral, R., Santos, G. W. and Colvin, O. M. (1989) Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation, Cancer Chemother. Pharmacol., 25, 55.
51. Martell, R. W., Sher, C., Jacobs, P. and Monteagudo, F. (1987) High-dose busulfan and myoclonic epilepsy. Ann. Intern. Med., 106, 173.
52. Sureda, A., Perez de Oteyza, J., Larana, J. G. and Odriozola, J. (1989) High-dose busulfan and seizures. Ann. Intern. Med., 111, 543.
53. Marcus, R. E. and Goldman, J. M. (1984) Convulsions due to highdose busulfan. Lancet, II, 1463.
54. De la Camara, R., Tomas, J. F., Figuera, A., Berberana, M. and Femandez-Ranada, J. M. (1991) High-dose busulfan and seizures. Bone Marrow Transplant., 7, 363.
55. Beelen, D. W., Quabeck, K., Graeven, U., Sayer, H. G., Mahmoud, H. K. and Schaefer, U. W. (1989) Acute toxicity and first clinical results of intensive postinduction therapy using modified busulfan and cyclophosphamide regimen with autologous bone marrow rescue in first remission of acute myeloid leukemia. Blood, 74, 1507.
56. Thomas, A. E., Patterson, J., Prentice, H. G., Brenner, M. K., Ganczakowski, M., Hancock, J. F., Pattinson, J. K., Blacklock, H. A. and Hopewell, J. P. (1987) Haemorrhagic cystitis in bone marrow transplantation patients: possible increased risk associated with prior busulfan therapy. Bone Marrow Transplant., 1, 347.
57. 14C-busulfan in isolated perfused rat liver. Eur. J. Drug Metab. Phannacokinet., 12, 71.
58. Hassan, M. and Ehrsson, H. (1987) Urinary metabolites of busulfan in the rat. Drug Metab. Dispos., 15, 399.
59. 11C]-busulfan in cynomolgus monkey and in the brain of a human patient. Cancer Chemother. Pharmacol., 30, 81.
60. Hassan, M., Öberg, G., Ehrsson, U., Ehrnebo, M., Wallin, I., Smedmyr, B., Tötterman, T., Eksborg, S. and Simonsson, B. (1989) Pharmacokinetic and metabolic studies of high-dose busulfan in adults. Eur. J. Clin. Pharmacol., 36, 525.
61. Hassan, M., Öberg, G., Békàssy, A. N., Aschan, J., Ehrsson, H., Ljungman, P., Lönnerholm, G., Smedmyr, B., Taube, A., Wallin, I. and Simonsson, B. (1991) Pharmacokinetics of high-dose busulfan in relation to age and chronopharmacology. Cancer Chemother. Pharmacol., 28, 130.
62. Vassal, G., Gouyette, A., Hartmann, O., Pico, J. L. and Lemerle, J. (1989) Pharmacokinetics of high-dose busulfan in children. Cancer Chemother. Pharmacol., 24, 386.
63. Grochow, L. B., Krivit, W., Whitley, C. B. and Blazar, B. (1990) Busulfan disposition in children. Blood, 75, 1723.
64. Shaw, P. J., Scharping, C. E., Brian, R. J. and Earl J. W. (1994) Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood, 84, 2357.
65. Grochow, L. B. (1993) Busulfan disposition: The role of therapeutic drug monitoring in bone marrow transplantation induction regimens. Semin. Oncol., 20, 18.
66. Regazzi, M. B., Locatelli, F., Buggia, I., Bonetti, F., Zecca, M., Pregnolato, M. and Quaglini, S. (1993) Disposition of high-dose-busulfan in pediatric patients undergoing bone marrow transplantation. Clin. Phannacol. Therap., 53, 45.
67. Vassal, G., Fischer, A., Challine, D., Boland, I., Ledheist, F., Lemerle, S., Vilmer, E., Rahimy, C., Souilette, G., Gluckman, E., Michel, G., Deroussent, A. and Gouyette, A. (1993) Busulfan disposition below the age of three: Alteration in children with lysosomal storage disease. Blood, 82, 1030.
68. Shaw, P. J., Hugh-Jones, K., Hobbs, J. R., Downie, C. J. C. and Bames, R. (1986) Busulfan and cyclophosphamide cause little early toxicity during displacement bone marrow transplantation in fifty children. Bone Marrow Transplant., 1, 193.
69. Shaw, P. J., Hugh-Jones, K., Barrett, A. J., Desai, S. J. S. and Hobbs, J. R. (1985) Experience with busulfan and cyclophophamide as pre-graft conditioning regime in inborn errors of metabolism. Exp. Hematol., 13, 92.
70. Ehrsson, H. and Hassan, M. (1983) Determination of busulfan in plasma by GC-MS with Selected-Ion Monitoring. J. Pharm. Sci., 72, 1203.
71. Vassal, G. and Gouyette, A. (1988) Gas chromatographic-mass spectrometric assay for busulfan in biological fluids using a deuterated internal standard. J. Chromatogr., 428, 357.
72. Hassan, M. and Ehrsson, H. (1983) Gas Chromatographic determination of busulfan in plasma with electron-capture detection. J. Chromatogr., 277, 374.
73. Chen, T.-L., Grochow, L. B., Hurowitz, L. A. and Brundrett, R. B. (1988) Determination of busulfan in human plasma by gas chromatography with electron-capture detection. J. Chromatogr., 425, 303.
74. Embree, L., Burns, R. B., Heggie, J. R., Phillips, G. L., Reece, D. E., Spinelli, J. J., Hartley, D. O., Hudon, N. J. and Goldie, J. H. (1993) Gas-chromatographic analysis of busulfan for therapeutic drug monitoring. Cancer Chemother. Phannacol., 32, 137.
75. Henner, W. D., Furlong, E. A., Flaherty, M. D. and Shea, T. C. (1987) Measurament of busulfan in plasma by high-performance liquid chromatography. J. Chromatogr., 416, 426.
76. Kazemifard, A. G. and Morgan, D. J. (1990) Determination of busulfan in plasma by high performance liquid chromatography. J. Chromatogr., 528, 274.
77. MacKichan, J. J. and Bechtel, T. P. (1990) Quantitation of busulfan in plasma by high-performance liquid chromatography. J. Chromatogr., 532, 424.
78. Blanz, J., Rosenfeld, C., Proksch, B. and Ehninger, G. (1990) Quatitation of busulfan in plasma by high-performance liquid chromatography using postcolumn photolysis. J. Chromatogr., 532, 429.
79. Pichini, S., Altieri, I., Bacosi, A., Di Carlo, S., Zuccaro, P., Iannetti, P. and Pacifici, R. (1992) High-performance liquid chromatographic-mass spectrometric assay of busulfan in serum and cerebrospinal fluid. J. Chromatogr., 581, 143.
80. Wheeler, G. P. (1962) Studies related to the mechanisms of action of cytotoxic alkylating agents: A review. Cancer Res., 22, 651.
81. Roberts, J. J. and Warwick, G. P. (1961) The mode of action of alkylating agents - III: The formation of 3-hydroxy-tetrahydrothiophene-1:1-dioxide from 1:4-dimethanesulphonyloxybutane (Myleran), S-ßL-alanyltetrahydrothiophenium mesylate, tetrahydrothiophene and tetrahydrothiophene-1:1-dioxide in the rat, rabbit and mouse. Biochem. Pharmacol., 6, 217.
82. Trams, E. G., Nadkarni, M. V., deQuattro, V., Maengwyn-Davies, G. D. and Smith, P. K. (1959) Dimethanesulphonoxybutane (Myleran), Preliminary studies on distribution and metabolic fate in the rat. Biochem. Pharmacol., 2, 7.
83. 35-labeled Myleran (busulfan) in normal and tumor bearing rats. J. Pharmacol. Exp. Ther., 120, 229.
84. 35S in the rat, mouse and rabbit. Biochem. Pharmacol., 5, 27.
85. Vodopick, H., Hamilton, H. E. and Jackson, H. L. (1969) Metabolic fate of tritiated busulfan in man. J. Lab. Clin. Med., 73, 266.
86. Nadkarni, M. V., Trams, E. G. and Smith, P. K. (1959) Preliminary studies on the distribution and fate of TEM, TEPA, and Myleran in the human. Cancer Res., 19, 713.
87. Ehrsson, H., Hassan, M., Ehrnebo, M. and Beran, M. (1983) Busulfan kinetics. Clinical Pharmacol. Ther., 34, 86.
88. Hassan, M., Ljungman, P., Ringdén, O., Syrüčková, Z., Békàssy, A., Stary, J., Wallin, I. and Kållberg, N. (1994) Busulfan Bioavaibility. Blood, 84, 2144.
89. Ehrsson, H. and Hassan, M. (1984) Binding of busulfan to plasma proteins and blood cells. J. Pharm. Pharmacol., 36, 694.
90. Friis-Hansen, B. (1961) Body water compartments in children: changes during growth and related changes in body composition. Pediatrics, 28, 169.
91. Maxwell, G. M. (1989) Paediatric drug dosing: bodyweight versus surface area. Drugs, 37, 113.
92. Hassan, M. and Ehrsson, H. (1986) Degradation of busulfan in aqueous solution. J. Pharm. Biomed. Anal., 4, 95.
93. Cheymol, G. (1993) Clinical pharmacokinetics of drugs in obesity. An update. Clin. Phannacokinet., 25, 103.
94. Blanchard, J. and Sawers, S. J. A. (1983) Comparative pharmacokinetics of caffeine in young and elderly men. J. Phannacokinet. Biopharm., 11, 109.
95. Grygiel, J. J., Ward, H., Ogborne, M., Goldin, A. and Birkett, D. J. (1983) Relationships between plasma theophylline clearance, liver volume and body weight in children and adults. Eur. J. Clin. Pharmacol., 24, 529.
96. Rylance, G. W., Moreland, T. A., Cowan, M. D. and Clark, D. C. (1982) Liver volume estimation using ultrasound scanning. Arch. Dis. Child., 57, 283.
97. Roberts, C. J. C., Jackson, L., Halliwell, M. and Branch, R. A. (1976) The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man. Br. J. Clin. Pharmacol., 3, 907.
98. Schuler, U., Schroer, S., Kuhnle, A., Blanz, J., Mewes, K., Kumbier, I., Proksch, B., Zeller, K-P. and Ehninger, G. (1994) Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant., 14, 759.
99. Wadhwa, N. K., Schroeder, T. J., O'Flaherty, E., Pesce, A. J., Myre, S. A. and First, M. R. (1987) The effect of oral metoclopramide on the absorption of cyclosporine. Transplant., 43, 211.
100. Manara, A. R., Shelly, M. P., Quinn, K. and Park, G. R. (1988) The effect of metoclopramide on the absorption of oral controlled release morphine. Br. J. Clin. Pharmacol., 25, 518.
101. Fitzsimmons, W. E., Ghalie, R. and Kaizer, H. (1990) Anticonvulsants and busulfan. Ann. Intern. Med., 112, 552.
102. Fitzsimmons, W. E., Ghalie, R. and Kaizer, H. (1990) The effect of hepatic enzyme inducers on busulfan neurotoxicity and myelotoxicity. Cancer Chemother. Pharmacol., 27, 226.
103. Hassan, M., Öberg, G., Björkholm, M., Wallin, I. and Lindgren, M. (1993) Influence of prophylactic anticonvulsant therapy on high-dose busulfan kinetics. Cancer Chemother. Pharmacol., 33, 181.
104. Grigg, A. P., Shepherd, J. D. and Phillips, G. L. (1989) Busulfan and phenytion. Ann. Intern. Med., 111, 1049.
105. Tiberghien, P., Flesch, M. and Cahn, J-Y. (1992) More on high-dose busulfan and seizure prophylaxis. Bone Marrow Transplant., 9, 147.
106. Ross, W. C. J. (1953) The chemistry of cytotoxic alkylating agents. In Advances in cancer research, editied by J. P. Greenstein and A. Haddow, pp. 397-446, Academic Press N.Y.
107. Hudson, R. F., Timmis, G. M. and Marshall, R. D. (1958) A physico-chemical investigation into the biological action of Myleran and related sulphonic acid esters. Biochem. Pharmacol., 1, 48.
108. Dunn, C. D. R. (1974) The chemical and biological properties of busulfan ("Myleran"). Exp. Hematol., 2, 101.
109. Marchand, D. H. and Abdel-Monem, M. M. (1985) Glutathione S-transferases catalyzed conjugation of 1,4-disubstituted butanes with glutathione in vitro. Biochem. Biophys. Res. Commun., 128, 360.
110. Onkenhout, W., van Loon, W. M. G. M., Buijs, W., van der Gen, A. and Vermeulen, N. P. E. (1986) Biotransformation and quantitative determination of sulfur-containing metabolites of 1,4-dibromobutane in the rat. Drug Metab. Dispos., 14, 608.
111. Hassan, M., Ehrsson, H., Wallin, I. and Eksborg, S. (1988) Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain. Eur. J. Drug Metab. Pharmacokinet., 13, 301.
112. 2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood, 79, 2475.
113. Yeager, A. M., Wagner, J. E. Jr., Graham, M. L., Jones, R. J., Santos, G. W. and Grochow, L. B. (1992) Optimization of busulfan dosage in children undergoing bone marrow transplantation: A pharmacokinetic study of dose escalation. Blood, 80, 2425.
114. Jones, R. J., Lee, K. S. K., Beschorner, W. E., Vogel, V. G., Grochow, L. B., Braine, H. G., Vogelsang, G. B., Sensenbrenner, L. L., Santos, G. W. and Saral, R. (1987) Venooclusive disease of the liver following bone marrow transplantation. Transplant, 44, 778.
115. Méresse, V., Hartmann, O., Vassal, G., Benhamou, E., Valteau, D., Brugieres, L. and Lemerle J. (1992) Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant., 10, 135.
116. Vassal, G., Deroussent, A., Hartman, O., Challine, D., Benhamou, E., Valteau-Couanet, D., Brugiéres, L., Kalifa, C., Gouyette, A. and Lemerle, J. (1990) Dose-dependent neurotoxicity of high-dose busulfan in children: A clinical and pharmacological study. Cancer Res., 50, 6203.
117. Ljungman, P., Hassan, M., Bekassy, A. N., Ringden, O. and Öberg, G. (1995) Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants. Bone Marrow Transplant., 15, 869.
118. Atkinson, K., Biggs, J., Noble, G., Ashby, M., Concannon, A. and Dodds, A. (1987) Preparative regimens for marrow transplantation containing busulfan are associated with haemorrhagic cystitis and hepatic veno-occlusive disease but a short duration of leucopenia and little oro-pharyngeal mucositis. Bone Marrow Transplant., 2, 385.
119. Yeager, A. M., Shinn, C., Farmer, E. R., Wingard, J. R. and Yeager, M. J. (1992) Growth retardation and depigmentation of hair after high-dose busulfan and congenic hematopoietic cell transplantation in mice. Bone Marrow Transplant., 9, 199.
120. Wingard, J. R., Plotnick, L. P., Freemer, C. S., Zahurak, M., Piantadosi, S., Miller, D. F., Vriesendorp, H. M., Yeager, A. M. and Santos, G. W. (1992) Growth in children after bone marrow transplantation: Busulfan plus cyclophosphamide versus cyclophosphamide plus total body irradiation. Blood, 79, 1068.
121. Sanders and the Seattle Marrow transplant Team. (1991) The Impact of marrow transplant preparative regimens on subsequent growth and development. Semin. Hematol., 28, 244, 1991.
122. Copelan, E. A. (1992) Conditioning regimens for allogeneic bone marrow transplantation. Blood Reviews, 6, 234.
123. Hassan, M., Ehrsson, H., Smedmyr, B., Tötterman, T., Wallin, I., Öberg, G. and Simonsson, B. (1989) Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy. Bone Marrow Transplantat., 4, 113.
124. 11C-labeling of busulfan. Int. J. Rad. Appl. Instrum. [A], 42, 1055.
125. Kalifa, C., Hartman, O., Demeocq, F., Vassal, G., Couanet, D., Terrier-Lacombe, M. J., Valteau, D., Brugieres, L. and Lemerle, J. (1992) High-dose busulfan and thiotepa with autologous bone marrow transplantation in childhood malignant brain tumors: a phase II study. Bone Marrow Transplant., 9, 227.
126. Tutschka, P. J., Copelan, E. A. and Klein, J. P. (1987) Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood, 70, 1382.
127. Morgan, M., Dodds, A., Atkinson, K., Szer, J., Downs, K. and Biggs, J. (1991) The toxicity of busulfan and cyclophosphamide as the preparative regimen for bone marrow transplantation. Br. J. Haematol., 77, 529.
128. Biaise, D., Maraninchi, D., Archimbaud, E., Reiffers, J., Devergie, A., Jouet, J. P., Milpied, N., Attal, M., Ifrah, N., Kuentz, M., Dauriac, C., Bordigoni, P., Gratecos, N., Guilhot, F., Guyotat, D., Gouvernet, J. and Gluckman, E. (1992) Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: A randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: A report from the Groupe d'Etudes de la Greffe de Moelle Osseuse. Blood, 79, 2578.
129. Ringdén, O., Ruutu, T., Remberger, M., Nikoskelainen, J., Volin, L., Vindeløv, L., Parkkali, T., Lenhoff, S., Sallerfors, B., Ljungman, P., Mellander, L. and Jacobsen, N. (1994) A randomized trial comparing busulfan versus total body irridation as conditioning in allogenic marrow transplantation recipient with hematological malignancies. A report from the Nordic Bone Marrow Transplantation Group. Blood, 83, 2723.
130. Bostrom, B. and Blazar, B. (1992) Role of busulfan pharmacokinetics on outcome after bone marrow transplantation for acute myelogenous leukemia. Blood, 80, 2947.